Our Pipeline



Tibulizumab ZB-106

A tetravalent, bispecific dual-antagonist antibody engineered by the fusion of TALTZ® (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF.

Man looking in a microscope

An anti-IL-7Rα inhibitor that has the potential to impact diseases driven by IL-7 and TSLP biological pathways.

Man looking intently into a miscroscope

A fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent (e.g., RAGE) inflammation.

“Zura Bio is focused on the development of therapies in challenging immunological conditions by deeply interrogating the therapeutic mechanism of action and pairing that with those patients with greatest need. This represents a unique opportunity for us to bring life-changing therapies to patients.”

Michael Howell, PhD
Chief Scientific Officer & Head of Translational Medicine